StockData
Kiniksa Pharmaceuticals International, plc logo

Kiniksa Pharmaceuticals International, plc (KNSA) stock

KNSANasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 27, 2026Score 14/30461% above fair value
$94.23−2.10 (-2.18%)

Close on Nov 16, 2026Market cap $14.81BP/E 72.5Yield –

Kiniksa Pharmaceuticals International operating margin

Operating margin is operating income as a percentage of revenue.

Kiniksa Pharmaceuticals International's operating margin for the twelve months ending Sep 30, 2026 was 13.8%. For fiscal 2025 it was 11.4%, against -10.8% the year before. The highest annual figure on record is 11.4% in fiscal 2025.

Annual operating margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 202511.4%+22.2
FY2024Dec 31, 2024-10.8%−1.5
FY2023Dec 31, 2023-9.3%−13.8
FY2022Dec 31, 20224.4%+410.8
FY2021Dec 31, 2021-406.4%–

Quarterly operating margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q3 FY2026Sep 30, 202619.0%+5.7
Q2 FY2026Jun 30, 202611.2%−1.7
Q1 FY2026Mar 31, 202613.7%+4.0
Q4 FY2025Dec 31, 20259.8%+25.5
Q3 FY2025Sep 30, 202513.3%+21.9
Q2 FY2025Jun 30, 202512.9%+13.0
Q1 FY2025Mar 31, 20259.6%+30.3
Q4 FY2024Dec 31, 2024-15.7%−15.8
Q3 FY2024Sep 30, 2024-8.6%+7.7
Q2 FY2024Jun 30, 2024-0.1%+4.3
Q1 FY2024Mar 31, 2024-20.7%+2.4
Q4 FY2023Dec 31, 20230.1%−9.7
Q3 FY2023Sep 30, 2023-16.3%−63.1
Q2 FY2023Jun 30, 2023-4.4%+67.4
Q1 FY2023Mar 31, 2023-23.2%+49.3
Q4 FY2022Dec 31, 20229.8%+202.5
Q3 FY2022Sep 30, 202246.8%+300.4
Q2 FY2022Jun 30, 2022-71.8%+454.6
Q1 FY2022Mar 31, 2022-72.4%–
Q4 FY2021Dec 31, 2021-192.8%–
Q3 FY2021Sep 30, 2021-253.6%–
Q2 FY2021Jun 30, 2021-526.4%–

More Kiniksa Pharmaceuticals International figures

See a number that looks wrong?